221 related articles for article (PubMed ID: 11712625)
1. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
Stein DJ; Montgomery SA; Kasper S; Tanghoj P
Int Clin Psychopharmacol; 2001 Nov; 16(6):357-61. PubMed ID: 11712625
[TBL] [Abstract][Full Text] [Related]
2. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
3. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
4. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
5. Beyond depression: citalopram for obsessive-compulsive disorder.
Pato MT
Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
[TBL] [Abstract][Full Text] [Related]
6. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
[TBL] [Abstract][Full Text] [Related]
7. Citalopram in refractory obsessive-compulsive disorder: an open study.
Marazziti D; Dell'Osso L; Gemignani A; Ciapparelli A; Presta S; Nasso ED; Pfanner C; Cassano GB
Int Clin Psychopharmacol; 2001 Jul; 16(4):215-9. PubMed ID: 11459335
[TBL] [Abstract][Full Text] [Related]
8. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
9. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Thomsen PH
J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Alaghband-Rad J; Hakimshooshtary M
Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
[TBL] [Abstract][Full Text] [Related]
11. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
13. New pharmacotherapeutic approaches to obsessive-compulsive disorder.
Figee M; Denys D
CNS Spectr; 2009 Feb; 14(2 Suppl 3):13-23. PubMed ID: 19238126
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
[TBL] [Abstract][Full Text] [Related]
16. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
[TBL] [Abstract][Full Text] [Related]
18. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
[TBL] [Abstract][Full Text] [Related]
19. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial.
Khan MN; Hotiana UA; Ahmad S
J Ayub Med Coll Abbottabad; 2007; 19(4):58-63. PubMed ID: 18693600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
